These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26429303)

  • 1. Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review.
    Cosway B; Paleri V; Wilson J
    J Laryngol Otol; 2015 Nov; 129(11):1046-52. PubMed ID: 26429303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Crystallization test in patients with head and neck neoplasms].
    Kuczkowski J; Zaorski P; Betlejewski A
    Otolaryngol Pol; 1995; 49 Suppl 20():121-4. PubMed ID: 9454116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in chemotherapy for head and neck cancer.
    Bhide SA; Nutting CM
    Oral Oncol; 2010 Jun; 46(6):436-8. PubMed ID: 20400360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers.
    Awada A; Lalami Y
    Curr Opin Oncol; 2005 May; 17(3):209-11. PubMed ID: 15818162
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacotherapy of head and neck squamous cell carcinoma.
    Pan Q; Gorin MA; Teknos TN
    Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck.
    Ferruzzi E; Franceschini R; Cazzolato G; Geroni C; Fowst C; Pastorino U; Tradati N; Tursi J; Dittadi R; Gion M
    Eur J Cancer; 2003 May; 39(7):1019-29. PubMed ID: 12706373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
    Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
    Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
    Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
    Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
    Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
    Henriksson E; Baldetorp B; Borg A; Kjellen E; Akervall J; Wennerberg J; Wahlberg P
    Acta Oncol; 2006; 45(3):300-5. PubMed ID: 16644573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating markers in squamous cell carcinoma of the head and neck: a review.
    Rassekh CH; Johnson JT; Eibling DE
    Eur J Cancer B Oral Oncol; 1994 Jan; 30B(1):23-8. PubMed ID: 9135969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in head and neck squamous cell carcinoma--a review.
    Safdari Y; Khalili M; Farajnia S; Asgharzadeh M; Yazdani Y; Sadeghi M
    Clin Biochem; 2014 Sep; 47(13-14):1195-202. PubMed ID: 24912050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.